Board Approves Final Investment Decision for Phoenix ISR Uranium Mine
Source: HoldCo Markets 02/26/2026
Denison Mines Corp. (DML:TSX; DNN:NYSE.MKT) advances to the construction phase with production expected by mid-2028, as HoldCo Markets raises its price target. Read on to see the new target.
On February 25, 2026, HoldCo Markets published a research note on Denison Mines Corp. (DML:TSX; DNN:NYSE.MKT) following the company’s announcement that its Board of Directors has made a Final Investment Decision (FID) to proceed with construction of the Phoenix ISR uranium mine in the Athabasca Basin. The firm maintains a positive view on the company and raised its 12-month price objective to CA$5.80 per share from CA$4.95 previously.
The FID marks the culmination of nearly a decade of development work on the Phoenix ISR Project. With all necessary provincial and federal approvals secured and required materials procured, site preparation and construction are expected to begin in March 2026. The construction period is estimated at approximately 24 months, with ISR uranium production from Phoenix expected by mid-2028. HoldCo Markets estimates the project will produce 56 million pounds of uranium over a 10-year life of mine, making it one of the more significant uranium mines globally and the first operating ISR mine in the Athabasca Basin. Longer term, the firm expects Denison’s Gryphon underground mine to begin production in 2034.
Earlier in January, Denison provided updated capital cost estimates for the project. The total post-FID initial capital estimate is now approximately CA$600 million at a Class 2 cost estimate level of precision, which represents a 20% increase relative to the 2023 Phoenix Feasibility Study after adjusting for inflation. The updated estimate includes CA$65 million in contingency funds and owners’ reserves. Notably, the construction timeline has been maintained at approximately 24 months despite the cost increases. A key refinement from the 2023 feasibility study is the planned installation of large-diameter wells throughout the Phase 1 mining area, enabling each well to function as either an injection or recovery well.
HoldCo Markets increased its long-term uranium price assumption to US$100/lb from US$90/lb previously and maintains a targeted NAV multiple of 1.40x. The firm notes that Denison shares have delivered a year-to-date performance of +62%, topping all peers in the large-cap uranium space.
At the most recent close of CA$5.89 on February 24, the new CA$5.80 price objective implies approximately 1% downside, leading the firm to conclude that shares are “currently fairly valued as much of the FID decision was incrementally getting factored in over the course of this year.” Denison currently trades at a 1.43x P/NAV multiple. The company has a market capitalization of approximately CA$5.3 billion on a basic basis and an enterprise value of CA$3.7 billion, with 896.57 million basic shares outstanding.
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
Important Disclosures:
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
Disclosures for HoldCo Markets, Denison Mines Corp., February 25, 2026
The following Terms and Conditions govern the use by readers, clients, subscribers and any other use of HoldCo Markets Advisory Inc.’s (“HoldCo Markets” or “the firm”) products and associated content which is made internally and selectively distributed/accessible via holdcomarkets.com, email and/or via select social media. Any written content contained herein should be viewed strictly as analysis, observation & opinion and not in any way as investment advice. HoldCo Markets is neither a qualified financial advisor, broker or legal advisor. All information, data and reports should be strictly seen as for informational purposes only and should not be considered in any way as investment advice or a solicitation for any security. HoldCo Markets does not make any recommendations, the firm only offers opinions. All content encompassing reports, writings and opinions are based on what the firm deems as reliable sources such as current news/corporate events, management interviews, SEC/SEDAR or any other regulatory filing and any other source deemed credible by the firm’s publishing analysts given their significant industry experience. HoldCo Markets has not been provided with any material non-public information from any company mentioned in the report. This report contains “forward-looking” statements. Company conclusions may involve forward-looking statements concerning future company or industry performance. Though the forward looking statements are based on fair and reasonable assumptions, actual performance or results may differ. Be reminded that market volatility is inherent with investing. Past performance is no guarantee of future performance. As such, an investment in any company mentioned in the above report should be viewed as speculative, and entered into only by those who can handle potential loss of capital. Recipients of any HoldCo Markets content looking to act on any of our opinions should consider whether any information contained in this report is suitable for their particular investing circumstance. The views and opinions expressed herein are company specific and subject to change without notice. All material contained on this website and disseminated through email or social media is strictly for informational purposes only. One should not take any financial decisions based solely on what was written from this above report, rather one should consider whether any information contained in this report is suitable for their particular investing circumstance and should seek professional advice. Volatility and the possibility of loss is inherent with any investment decision, HoldCo Markets accepts no liability for any potential direct or indirect loss arising from the use of our research, website or any additional in-house content. Research Notes: HoldCo Markets did not receive any form of compensation from the company or companies written about in Research Notes. Conclusions and opinions expressed in the reports have been formulated independently and objectively. Research Notes are strictly an expression of our views and opinions. No compensation was received for any Research Notes publication or for its distribution. As a non IIROC registered company, HoldCo Markets Advisory Inc. neither provides investment banking services nor does it make a market in any securities written about in Research Notes. Spotlight Research: Holdco Markets publishes and distributes Spotlight Research which is a differentiated research product which is specifically issuer-paid. Monetary compensation has been received for a twelve-month research coverage period. The purpose of Spotlight Research is to highlight growth companies which have been largely overlooked by the larger broker/dealers, largely due to constraints related to size and liquidity. Spotlight Research is strictly an expression of our views and opinions. HoldCo Markets’ publishing analysts retain full control over the conclusions and opinions regarding this issuer-paid research. As a non IIROC registered company, HoldCo Markets Advisory Inc. neither provides investment banking services nor does it make a market in any securities written about in Spotlight Research. Holdco Markets, any publishing analyst or any HoldCo Markets Board member may at one point hold a direct or indirect position by way of equity, options, warrants or debt in any or none of the companies mentioned in either Research Notes or Spotlight Research. No person with any affiliation to HoldCo Markets serves in any capacity as an officer or Director in any of the companies mentioned in the above document. The distribution of any HoldCo Markets content has no relation to the distribution of securities nor is it in any way a solicitation to bur or sell any security. Reprinting any content or information from this report is strictly prohibited without permission. For more information or to receive future reports, please visit Home (holdcomarkets.com)
( Companies Mentioned: DML:TSX; DNN:NYSE.MKT, )
Source: https://www.streetwisereports.com/article/2026/02/26/board-approves-final-investment-decision-for-phoenix-isr-uranium-mine.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

